AstraZeneca and insitro announced on Oct. 15, 2026, a strategic drug discovery collaboration and licensing agreement that ...
As GLP-1 therapies evolve from single-agonist peptides toward dual and triple agonists, formulation and CMC teams face a more ...
The FDA’s Rare Disease Framework Initiative brings risk-based CMC review and pre-approval inspections into scope for sponsors ...
In the latest installment of the PharmTech AI Pulse Check video series, Associate Editorial Director Christopher Cole is ...
Boyang Wang, Immortal Dragons, discusses how the FDA’s Expedited IND Pilot must prove efficiency as sponsors chase the fastest route to valid first-in-human data. Boyang Wang, founder of Immortal ...
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating ...
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a ...
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral ...
PharmTech covered one of the industry’s biggest events this week, as CPHI Milan was in full force with experts arguing that ...
In US regulatory news, the FDA opened applications for its Expedited IND Pilot on September 15. 1 The program pairs drug ...
The FDA's expanding embrace of new approach methodologies (NAMs) is forcing pharmaceutical manufacturing and quality teams to rethink how preclinical and CMC data will be generated, validated, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results